The Role of Urine Drug Testing for Patients on Opioid Therapy

Pain Practice

Volumn 10, Issue 6, 2010, Pages 497-507

  Pergolizzi, Joseph ^a,b   Pappagallo, Macro ^c   Stauffer, Joseph ^a,b   Gharibo, Christopher ^d   Fortner, Neil ^e   De Jesus, Mathew N ^b   Brennan, Michael J ^f   Richmond, Charlotte ^g   Hussey, Desmond ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Air Force Research Laboratory   (United States)

^f BRIDGEPORT HOSPITAL   (United States)

^g Biomedical Research and Education Foundation LLC   (United States)

^h Neuroscience and Spine Associates   (United States)

Author keywords

Analgesics; Narcotics; Opioid; Opioid analgesics; Opioid misuse; Opioid therapy; Opioids; Pain; Pain clinics; Urine drug testing

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BUPRENORPHINE; CANNABIS; COCAINE; CODEINE; DEXTROPROPOXYPHENE; DIAMORPHINE; DRUG METABOLITE; FENTANYL; HYDROCODONE; HYDROMORPHONE; ILLICIT DRUG; MORPHINE; OPIATE; OPIATE AGONIST; OXYCODONE; OXYMORPHONE; PETHIDINE; TAPENTADOL; TRAMADOL;

ANALGESIA; ARTICLE; CHRONIC PAIN; DIAGNOSTIC VALUE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DETERMINATION; DRUG MEGADOSE; DRUG MISUSE; DRUG MONITORING; DRUG RESPONSE; DRUG SCREENING; DRUG URINE LEVEL; HEALTH CARE COST; HUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; URINALYSIS;

EID: 78049480350     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2010.00375.x     Document Type: Article

References (39)

1. Berman F, Carr DB, Cousins M. The role of opioids in pain management. Anesth Analg. 2007;105:1865-1866.
2. Auret K, Schlug SA. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging. 2005;22:641-654.
3. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manag. 2003;84:189-194.
4. Drug Enforcement Administration. Physician's Manual: An Informational Outline of the Controlled Substances Act of 1970. Washington, DC: US Department of Justice; 1990.
5. Chou R, Fanicullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
6. Compton P. The role of urine toxicology in chronic opioid analgesic therapy. Pain Manag Nurs. 2007;8:166-172.
7. Florida Senate 2009. Text of SB462. [WWW document]. URL [accessed on December 23, 2009]
8. CMS Manual System. (2004) Pub 100-04 medicare claims processing, transmittal 1884. [WWW document]. URL [accessed on January 8, 2010]
9. Centers for Medicare and Medicaid Services. (2009) Calendar year 2010. New Clinical Laboratory Fee Schedule Test Codes and Final Payment Determinations. [WWW document]. URL [accessed on January 8, 2010]
10. Adams NJ, Plane MB, Fleming MF, Mundt MP, Saunders LA, Stauffacher EA. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage. 2001;22:791-796.
11. Cone EJ, Caplan YH, Black DL, Robert T, Moser F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008;32:530-543.
12. Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007;23:173-179.
13. Fishbain D, Cutler RB, Rosomoff HL, Rosomoff R, Steele RN. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999;15:184-191.
14. Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D. Misuse of and dependence on opioids. Can Fam Physician. 2006;52:1081-1087.
15. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage. 2004;27:260-267.
16. Passik SD, Krish KL. Opioid therapy in patients with a history of substance abuse. CNS Drugs. 2004;18:13-25.
17. Macario A, Pergolizzi JV Jr. Urine drug testing in chronic pain patients taking opioids: a clinical practice update. Int J Pain Med Palliat Care. 2005;4:133-139.
18. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9:444-459.
19. Hoffmann NG, Olofsson O, Salen B, Wickstrom L. Prevalence of abuse and dependency in chronic pain patients. Int J Addict. 1995;30:919-927.
20. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006;9:1-39.
21. Dackis C, O'Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci. 2005;8:1431-1436.
22. American Academy of Pain Medicine, The American Pain Society, The American Society of Addiction Medicine. (2001) Definitions related to the use of opioids for the treatment of pain. Consensus Document. [WWW document]. URL [accessed on January 9, 2010]
23. Katz N, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97:1097-1102.
24. Cone EJ, Heit HA, Caplan YA, Gourlay D. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006;30:1-5.
25. Wasan AD, Michna E, Janfaza D, Greenfield S, Teter CJ, Jamison RN. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med. 2008;9:918-923.
26. Michna E, Ross EL, Hynes WL. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004;28:250-258.
27. Wasan AD, Butler SF, Budman SH, et al. Does report of craving opioid medication predict aberrant drug behavior among certain patients? Clin J Pain. 2009;25:193-198.
28. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among US adults: psychiatric, medical and substance abuse correlates. Drug Alcohol Depend. 2008;94:38-47.
29. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573-582.
30. Jamison RN, Butler SF, Budman SH, Edwards RR, Wasan AD. Gender differences in risk factors for aberrant prescription opioid use. J Pain. Nov. 26 [Epub ahead of print.
31. Couto JE, Romney MC, Leider HL, Sharma S, Goldfarb NI. High rates of inappropriate drug use in the chronic pain population. Popul Health Manag. 2009;12:185-190.
32. Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance abuse and mental health problems in primary care patients. Pain Med. 2008;9:1098-1106.
33. Gourlay DL, Caplan YH, Heit HA. (2006) Urine drug testing in clinical practice: dispelling the myths and designing strategies. CME activity, California Academy of Family Practice. [WWW document]. URL [accessed on November 9, 2009]
34. Shults TF. The Medical Review Officer Handbook. 8th ed. Research Triangle Park, NC: Quadrangle Research, LLC; 2002.
35. Tellioglu T. The use of urine drug testing to monitor patients receiving chronic opioid therapy for persistent pain conditions. Med Health R I. 2008;91:270-282.
36. Clark J. Thin-layer chromatography. (2007) [WWW document]. URL [accessed on January 7, 2010]
37. Clark J. (2007) High-performance liquid chromatography. [WWW document]. URL [accessed on January 7, 2010]
38. Hodgson BT, Walter L, Perrigo BJ. (2001) Toxicology report: a review 1999-2001. Royal Canadian Mounted Police Forensic Laboratory. Forensic Science Symposium. [WWW document]. URL [accessed on January 7, 2010]
39. Marquet P, Lachatre G. Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology. J Chromatogr B Biomed Sci Appl. 1999;733:93-118.